Stock listing
NASDAQ:CGEM Cullinan Therapeutics, Inc. Stock
Home listing (NASDAQ) of Cullinan Therapeutics, Inc.
Follow Cullinan Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CGEM
$8.89 USD -0.12 (-1.3%)
Close on Nov 20, 2026
- Day range
- $8.80 – $9.43 USDNov 20, 2026
- Volume
- 1.01M sharesNov 20, 2026
- Market cap
- $577.1M USDAt the close on Nov 20, 2026 · price × 64.92M shares outstanding
- 52-week range
- $8.48 – $23.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $16.02M USDMedian day 831,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CGEM · Home | $8.89 USD | -0.12 (-1.3%) | 1,009,932 | $8.84 | $9.43 | $8.80 | $9.01 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CGEM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.89 | -0.12 | -1.3% | $8.84 | $9.43 | $8.80 | 1,009,932 | |
| $9.01 | -0.265 | -2.9% | $9.17 | $9.514 | $8.81 | 1,063,904 | |
| $9.275 | -0.225 | -2.4% | $9.45 | $9.45 | $8.475 | 1,625,986 | |
| $9.50 | -0.78 | -7.6% | $10.11 | $10.28 | $9.46 | 866,715 | |
| $10.28 | +0.09 | +0.9% | $10.19 | $10.35 | $9.76 | 1,376,903 | |
| $10.19 | -1.16 | -10.2% | $11.04 | $11.12 | $10.11 | 1,135,106 | |
| $11.35 | +0.12 | +1.1% | $11.34 | $11.68 | $11.15 | 982,590 | |
| $11.23 | -0.50 | -4.3% | $11.71 | $12.04 | $10.95 | 810,360 | |
| $11.73 | +0.42 | +3.7% | $11.40 | $12.41 | $10.80 | 1,035,134 | |
| $11.31 | +0.51 | +4.7% | $11.09 | $11.77 | $10.69 | 755,506 | |
| $10.80 | -1.69 | -13.5% | $12.36 | $12.48 | $10.77 | 1,789,228 | |
| $12.49 | -3.26 | -20.7% | $15.99 | $16.29 | $11.92 | 2,203,294 | |
| $15.75 | +0.82 | +5.5% | $15.04 | $16.20 | $14.98 | 788,705 | |
| $14.93 | -0.10 | -0.7% | $15.13 | $15.35 | $14.63 | 730,766 | |
| $15.03 | -0.42 | -2.7% | $15.38 | $15.72 | $14.70 | 389,400 | |
| $15.45 | -0.11 | -0.7% | $15.60 | $16.19 | $15.35 | 459,700 | |
| $15.56 | +0.72 | +4.9% | $14.93 | $15.62 | $14.72 | 594,200 | |
| $14.84 | +0.30 | +2.1% | $14.66 | $14.98 | $14.28 | 488,100 | |
| $14.54 | +0.17 | +1.2% | $14.71 | $14.87 | $14.39 | 438,500 | |
| $14.37 | -0.55 | -3.7% | $14.95 | $14.95 | $13.86 | 485,200 | |
| $14.92 | +0.03 | +0.2% | $14.82 | $15.32 | $14.64 | 392,700 | |
| $14.89 | +0.06 | +0.4% | $14.92 | $15.26 | $14.64 | 691,000 | |
| $14.83 | +0.85 | +6.1% | $13.92 | $14.92 | $13.85 | 694,000 | |
| $13.98 | +1.05 | +8.1% | $13.02 | $14.00 | $12.77 | 862,500 | |
| $12.93 | -1.07 | -7.6% | $13.91 | $13.91 | $12.81 | 1,123,300 | |
| $14.00 | +0.36 | +2.6% | $13.62 | $14.18 | $13.46 | 972,100 | |
| $13.64 | -0.46 | -3.3% | $13.81 | $14.18 | $13.44 | 903,500 | |
| $14.10 | -0.85 | -5.7% | $14.86 | $14.93 | $14.08 | 590,300 | |
| $14.95 | -0.58 | -3.7% | $15.45 | $15.64 | $14.88 | 372,400 | |
| $15.53 | +0.07 | +0.5% | $15.41 | $15.95 | $15.24 | 567,500 | |
| $15.46 | -0.17 | -1.1% | $15.60 | $15.71 | $14.81 | 1,137,400 | |
| $15.63 | -0.62 | -3.8% | $15.95 | $16.46 | $15.47 | 808,200 | |
| $16.25 | +0.21 | +1.3% | $17.24 | $17.70 | $16.06 | 2,017,000 | |
| $16.04 | +0.53 | +3.4% | $15.59 | $16.55 | $15.13 | 1,083,000 | |
| $15.51 | +0.98 | +6.7% | $14.76 | $15.56 | $14.59 | 1,162,100 | |
| $14.53 | -0.82 | -5.3% | $15.22 | $15.39 | $14.49 | 910,800 | |
| $15.35 | +0.12 | +0.8% | $15.39 | $15.78 | $14.96 | 1,067,200 | |
| $15.23 | +0.28 | +1.9% | $15.00 | $15.44 | $14.68 | 1,244,400 | |
| $14.95 | +0.14 | +0.9% | $14.71 | $15.19 | $14.20 | 1,109,200 | |
| $14.81 | -0.63 | -4.1% | $15.62 | $15.62 | $14.67 | 1,715,500 | |
| $15.44 | -1.43 | -8.5% | $16.60 | $16.88 | $14.80 | 2,728,800 | |
| $16.87 | -4.80 | -22.2% | $21.67 | $21.67 | $16.78 | 2,593,300 | |
| $21.67 | +0.32 | +1.5% | $21.44 | $21.88 | $21.27 | 831,800 | |
| $21.35 | +0.27 | +1.3% | $21.45 | $21.79 | $20.98 | 763,900 | |
| $21.08 | -0.28 | -1.3% | $21.38 | $21.45 | $20.63 | 3,251,000 | |
| $21.36 | +0.73 | +3.5% | $21.06 | $21.58 | $20.81 | 756,700 | |
| $20.63 | +0.09 | +0.4% | $20.50 | $20.84 | $20.20 | 825,700 | |
| $20.54 | +0.14 | +0.7% | $20.38 | $20.71 | $19.64 | 1,060,500 | |
| $20.40 | -0.19 | -0.9% | $18.55 | $20.93 | $18.51 | 1,418,200 | |
| $20.59 | -0.41 | -2.0% | $21.16 | $21.34 | $20.10 | 1,090,400 | |
| $21.00 | -0.31 | -1.5% | $20.99 | $21.22 | $20.50 | 805,600 | |
| $21.31 | -0.38 | -1.8% | $21.30 | $21.80 | $21.08 | 1,278,700 | |
| $21.69 | -0.40 | -1.8% | $21.61 | $22.41 | $21.28 | 953,700 | |
| $22.09 | -0.07 | -0.3% | $21.88 | $22.30 | $21.77 | 562,200 | |
| $22.16 | -0.17 | -0.8% | $22.39 | $22.68 | $21.65 | 524,100 | |
| $22.33 | +0.54 | +2.5% | $21.88 | $22.79 | $21.75 | 769,700 | |
| $21.79 | -0.28 | -1.3% | $21.80 | $22.07 | $21.55 | 546,100 | |
| $22.07 | +0.37 | +1.7% | $21.50 | $22.23 | $21.34 | 682,500 | |
| $21.70 | -0.90 | -4.0% | $22.60 | $22.88 | $21.57 | 630,100 | |
| $22.60 | -0.25 | -1.1% | $22.55 | $22.96 | $22.19 | 471,900 | |
| $22.85 | -0.10 | -0.4% | $22.66 | $23.19 | $22.42 | 683,300 | |
| $22.95 | +1.13 | +5.2% | $22.16 | $23.06 | $22.16 | 519,255 | |
| $21.82 | +0.14 | +0.6% | $21.62 | $22.37 | $21.16 | 617,367 | |
| $21.68 | +0.30 | +1.4% | $21.72 | $22.11 | $21.40 | 758,100 | |
| $21.38 | -1.14 | -5.1% | $22.14 | $22.25 | $21.02 | 902,500 |
Splits
1 split · NASDAQ:CGEM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- NASDAQ:CGEM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 64 slides
Latest news
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Nov 12, 2026
Closed $10.28 (+0.9%) on Nov 13, 2026
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov 10, 2026
Closed $11.23 (-4.3%) on Nov 10, 2026
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Nov 9, 2026
Closed $11.73 (+3.7%) on Nov 9, 2026
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Nov 8, 2026
Closed $11.73 (+3.7%) on Nov 9, 2026
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Nov 4, 2026
Closed $12.49 (-20.7%) on Nov 4, 2026
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
Oct 27, 2026
Closed $14.84 (+2.1%) on Oct 27, 2026
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
Oct 19, 2026
Closed $13.98 (+8.1%) on Oct 19, 2026
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
Oct 8, 2026
Closed $15.46 (-1.1%) on Oct 8, 2026
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Oct 1, 2026
Closed $15.51 (+6.7%) on Oct 2, 2026
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Sep 24, 2026
Closed $15.44 (-8.5%) on Sep 24, 2026
Cullinan Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 130 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 22 decks · latest October 2026
Where Cullinan Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CGEM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CGEM | BOATS | United States | USD |
Valuation
Price/book 2.0× against a median of 2.4×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $289.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.45
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. · NASDAQ:CGEM | US$577.1M | US$289.6M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 1.45 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.6M | n/a | 106× | n/a | 2.9× | n/a | 0.4× | n/a |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Design Therapeutics, Inc. · NASDAQ:DSGN | US$577.6M | US$371.5M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.29 |
| Immix Biopharma, Inc. · NASDAQ:IMMX | US$577.0M | US$241.7M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.60 |
| Entera Bio Ltd. · NASDAQ:ENTX | US$574.8M | US$308.9M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | 0.76 |
| DBV Technologies SA · EURONEXT:DBV | US$571.8M | US$430.7M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.3M | US$232.4M | n/a | 765× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.8M | US$613.4M | 14.6× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Median of the others | US$573.3M | US$340.2M | 14.6× | 47.1× | 22.9× | 2.4× | −90.3% | 0.0× | 1.49 |
Forecasts
11 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 34.70 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.98 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Nadim Ahmed | President and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Andrew Allen | Member of the Compensation Committee |
| David Meek | Chair of the Nominating and Corporate Governance Committee |
| Mary Thistle | Chair of the Compensation Committee |
| Mittie Doyle | Member of the Nominating and Corporate Governance Committee |
| Stephen Webster | Chair of the Audit Committee |
| Tony Rosenberg | Member of the Audit Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −4.3% |
| Q2 2026 | Aug 6, 2026 · Before open | +1.9% |
| Q1 2026 | May 7, 2026 · Before open | −1.8% |
| Q4 2025 | Mar 5, 2026 | −3.4% |
| Q3 2025 | Nov 6, 2025 · Before open | +0.6% |
| Q2 2025 | Aug 7, 2025 · Before open | −10.8% |
| Q1 2025 | May 8, 2025 · Before open | +0.9% |
| Q4 2024 | Mar 12, 2025 · Before open | +4.7% |
| Q3 2024 | Nov 7, 2024 · Before open | −5.5% |
| Q2 2024 | Aug 8, 2024 · Before open | −1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | −10.9% |
| Q4 2023 | Mar 14, 2024 · Before open | −0.4% |
| Q3 2023 | Nov 8, 2023 · Before open | +0.8% |
| Q2 2023 | Aug 10, 2023 · Before open | −0.7% |
| Q1 2023 | May 11, 2023 · After close | +1.5% |
| Q4 2022 | Mar 9, 2023 · Before open | +0.1% |
| Q3 2022 | Nov 14, 2022 · Before open | +2.4% |
| Q2 2022 | Aug 10, 2022 · Before open | −0.8% |
| Q1 2022 | May 16, 2022 · Before open | +2.5% |
| Q4 2021 | Mar 17, 2022 · Before open | +4.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 64 slides | October 2026 |
| WCLC 2026 | Conference | 15 slides | September 2026 |
| Investor Presentation (September 2025) | Investor deck | 53 slides | Sep 4, 2025 |
| Technical Presentation (September 2025) | Technical | 17 slides | September 2025 |
| Technical Presentation (September 2025) | Technical | 14 slides | September 2025 |
| Merger or Acquisition (June 2025) | Merger or acquisition | 17 slides | Jun 4, 2025 |
| Investor Presentation (April 2025) | Investor deck | 58 slides | Apr 16, 2025 |
| Investor Presentation (April 2025) | Investor deck | 87 slides | Apr 16, 2025 |
| Investor Presentation (February 2025) | Investor deck | 57 slides | Feb 27, 2025 |
| Investor Presentation (January 2025) | Investor deck | 57 slides | Jan 28, 2025 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2024) | Investor deck | 55 slides | Oct 16, 2024 |
| Investor Presentation (September 2024) | Investor deck | 51 slides | Sep 17, 2024 |
| Corporate Update (June 2024) | Corporate update | 35 slides | Jun 3, 2024 |
| Investor Presentation (June 2024) | Investor deck | 48 slides | June 2024 |
| Investor Presentation (May 2024) | Investor deck | 38 slides | May 15, 2024 |
| Corporate Update (April 2024) | Corporate update | 25 slides | Apr 16, 2024 |
| Investor Presentation (April 2024) | Investor deck | 37 slides | Apr 16, 2024 |
| Cullinan Oncology — Corporate Update (May 2022) | Corporate update | 10 slides | May 12, 2022 |
| Cullinan Oncology — Technical Presentation (December 2021) | Technical | 18 slides | Dec 16, 2021 |
| Cullinan Oncology — Informa AET (December 2021) | Conference | 18 slides | Dec 14, 2021 |
| Cytokine Summit (September 2021) | Conference | 12 slides | Sep 22, 2021 |
| Cullinan Oncology — Technical Presentation (June 2021) | Technical | 17 slides | Jun 4, 2021 |
IPO
Went public as Cullinan Management, Inc. Priced at US$21.00 a share on Jan 7, 2021.
- Price
- US$21.00 a share
- Shares offered
- 11,900,000 shares of common stock
- Offering size
- US$249.9 million
- Underwriters' option
- Up to 1,785,000 more shares
- Underwriters
- MORGAN STANLEY, SVB LEERINK, EVERCORE ISI, H.C. WAINWRIGHT & CO. · In the order on the cover
- Shares delivered
- On or about Jan 12, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 2, 2020 |
| Filed publicly | Dec 18, 2020 |
| Amended 3 times | Newest Jan 6, 2021 |
| Shares registered with an exchange | Jan 6, 2021 |
| Declared effective by the SEC | Jan 7, 2021 |
| Final prospectus, with the price | Jan 11, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 11, 2021 |
| EFFECT · Notice that a registration is effective | Jan 7, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jan 7, 2021 |
| CERT · Exchange's certificate of listing | Jan 7, 2021 |
| CORRESP · Letter to the SEC | Jan 6, 2021 |
| S-1/A · Registration statement, amended | Jan 6, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 6, 2021 |
| UPLOAD · Letter from the SEC | Jan 5, 2021 |
| CORRESP · Letter to the SEC | Jan 4, 2021 |
| CORRESP · Letter to the SEC | Jan 4, 2021 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jan 4, 2021 |
| S-1/A · Registration statement, amended | Dec 28, 2020 |
| CORRESP · Letter to the SEC | Dec 18, 2020 |
| CORRESP · Letter to the SEC | Dec 18, 2020 |
| S-1 · Registration statement | Dec 18, 2020 |
| UPLOAD · Letter from the SEC | Dec 18, 2020 |
| DRSLTR · Letter to the SEC with a draft | Dec 9, 2020 |
| DRS/A · Draft registration statement, amended | Dec 9, 2020 |
| UPLOAD · Letter from the SEC | Dec 1, 2020 |
| DRS · Draft registration statement | Nov 2, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 11, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 18.9M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 311.0K | 306.0K | 310.0K | 93.0K | 53.0K | 62.0K | 70.0K | 43.0K | 0 | 0 |
| Gross profit | -311.0K | -306.0K | -310.0K | -93.0K | 18.9M | -62.0K | -70.0K | -43.0K | 0 | 0 |
| Research and development | 187.4M | 142.9M | 148.2M | 91.9M | 57.8M | 43.2M | 16.8M | 9.58M | ||
| Selling, general and administrative | 54.2M | 52.8M | 42.5M | 40.2M | 29.1M | 17.1M | 5.48M | 5.00M | 197.4K | 95.4K |
| Operating income | -241.6M | -196.9M | -191.1M | 144.6M | -68.0M | -60.3M | -22.3M | -14.6M | -197.4K | -95.4K |
| Depreciation and amortization | 311.0K | 306.0K | 310.0K | 93.0K | 53.0K | 62.0K | 70.0K | 43.0K | ||
| EBITDA | -241.3M | -196.6M | -190.8M | 144.7M | -67.9M | -60.3M | -22.2M | -14.5M | ||
| Interest expense | 562.4M | 65.4M | 888.0K | 0 | 0 | 0 | 0 | |||
| Income before tax | -219.9M | -167.5M | -169.2M | 151.3M | -67.5M | -59.5M | -21.7M | -14.2M | -316.7K | -109.5K |
| Income tax | 0 | 117.0K | -14.1M | 42.1M | 0 | -8.61M | -1.62M | 397.0K | 0 | 0 |
| Net income | -219.9M | -167.4M | -153.2M | 111.2M | -65.6M | -51.8M | -20.0M | -14.2M | -316.7K | -109.5K |
| Earnings per share, basic | -3.65 | -2.86 | -3.69 | 2.46 | -1.52 | -2.60 | -19.68 | -17.74 | ||
| Earnings per share, diluted | -3.69 | 2.38 | -1.52 | -2.60 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 88.3M | 83.0M | 98.4M | 156.2M | 59.8M | 168.2M | 63.3M | 33.8M | 91 | 118 |
| Short-term investments | 289.6M | 316.0M | 368.6M | 311.1M | 230.7M | 42.0M | 35.4M | 0 | ||
| Receivables | 3.00M | 5.40M | 3.34K | |||||||
| Inventory | -5.40M | |||||||||
| Current assets | 386.8M | 414.7M | 480.2M | 474.5M | 296.6M | 212.3M | 100.1M | 34.2M | 3.44K | 118 |
| Property, plant and equipment | 421.0K | 683.0K | 989.0K | 1.17M | 77.0K | 130.0K | 182.0K | 233.0K | ||
| Total assets | 448.4M | 621.8M | 484.2M | 561.1M | 437.2M | 214.7M | 100.5M | 34.6M | 3.44K | 118 |
| Accounts payable | 841.0K | 1.68M | 2.49M | 2.66M | 3.17M | 9.68M | 934.0K | 296.0K | 247.9K | 156.7K |
| Current liabilities | 37.7M | 30.6M | 28.1M | 22.5M | 11.7M | 14.3M | 2.52M | 1.32M | 247.9K | 156.7K |
| Long-term debt | 330.4K | 1.09M | ||||||||
| Total debt | 2.68M | 2.15M | 3.59M | 5.19M | ||||||
| Total liabilities | 39.6M | 31.5M | 30.3M | 26.1M | 11.8M | 14.4M | 140.4M | 55.3M | 578.3K | 1.24M |
| Shareholders' equity | 408.7M | 590.3M | 453.7M | 535.0M | 425.0M | 199.0M | -40.8M | -20.7M | -574.9K | -1.24M |
| Shares outstanding | 60.2M | 58.5M | 42.9M | 45.8M | 44.3M | 29.8M | 1.02M | 800.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -175.8M | -145.3M | -134.3M | -126.7M | -43.4M | -29.8M | -20.9M | -13.5M | -228.9K | -24.0K |
| Capital spending | -49.0K | 0 | -208.0K | -1.13M | 0 | -10.0K | -20.0K | -261.0K | 0 | 0 |
| Free cash flow | -175.8M | -145.3M | -134.5M | -127.8M | -43.4M | -29.8M | -20.9M | -13.8M | -228.9K | -24.0K |
| Cash from investing | 180.0M | -136.3M | 35.8M | 249.0M | -333.8M | -5.42M | -35.4M | -261.0K | ||
| Cash from financing | 1.09M | 266.2M | 40.8M | -25.9M | 268.8M | 140.1M | 85.7M | -29.0K | 228.9K | 22.0K |
| Share buybacks | -23.7M | 271.5M | -6.57M | -378.0K | -21.0K | 986.7K | 986.7K | |||
| Change in cash | 5.33M | -15.4M | -57.7M | 96.4M | -108.4M | 104.9M | 29.4M | -13.8M | -27 | -2.05K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 10, 2026 | Current report | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Apr 28, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 8, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 31, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| 8-K · Current report | Sep 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 7, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 5, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jun 4, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | May 31, 2024 | Other filings | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 16, 2024 | Insider trade | SEC |
| S-3 · Registration statement | May 16, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | May 16, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 16, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 16, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 30, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 29, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Apr 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 16, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Apr 2, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 14, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 14, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
This page holds 200 of 471 filings. Open Filings
Cap table
Built by 6ix from Cullinan Therapeutics, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 64,920,924
- Fully diluted
- 64,920,924
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 64,920,924 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 64,920,924 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Stephen Webster Other companies: NextCure, Inc. (Director · Since at least May 8, 2019); Gritstone bio, Inc. (Director · Apr 26, 2024 – Apr 4, 2025 · Past); Tcr2 Therapeutics Inc (Director · Apr 30, 2020 – Jun 1, 2023 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 2, 2022 · Past); Viking Therapeutics, Inc. (Director · Apr 28, 2015 – Jan 2, 2020 · Past); Spark Therapeutics Inc (CHIEF FINANCIAL OFFICER · Jan 29, 2015 – Dec 17, 2019 · Past); Optimer Pharmaceuticals Inc (Chief Financial Officer · Jun 25, 2012 – Oct 24, 2013 · Past); Adolor Corp (SVP, Finance & CFO · Sep 9, 2010 – Dec 12, 2011 · Past) | Chair of the Audit Committee · Since at least Jan 7, 2021 |
| Owen Hughes Other companies: AnaptysBio, Inc. (Member of the Audit Committee · Since at least May 11, 2026); XOMA Royalty Corporation (Chief Executive Officer, Director · Since at least Nov 11, 2024); C4 Therapeutics, Inc. (Director · Since at least Nov 16, 2023); ImageneBio, Inc. (Director · Dec 14, 2022 – Jun 7, 2024 · Past); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Radius Health, Inc. (Director · Apr 23, 2013 – Aug 15, 2022 · Past) | President and CEO, Director · Jan 7, 2021 – Jan 12, 2021 · Past |
| Mary Thistle Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Oct 28, 2021); Q32 Bio Inc. (Director · Since at least Mar 27, 2018); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past) | Chair of the Compensation Committee · Since at least Aug 8, 2024 |
| David Meek Other companies: uniQure N.V. (Chairman of the Board · Since at least Feb 25, 2021); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past); Entasis Therapeutics Holdings Inc (Director · Jun 10, 2020 – Jul 7, 2022 · Past) | Director · Since at least May 15, 2024 |
| Mary Kay Fenton Other companies: Tourmaline Bio Inc. (Chief Financial Officer · May 6, 2021 – Jul 3, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Jun 23, 2022 · Past); Achillion Pharmaceuticals Inc (Chief Financial Officer · Dec 12, 2011 – Feb 9, 2018 · Past) | Chief Financial Officer · Since at least Apr 29, 2024 |
| Nadim Ahmed Other companies: Disc Medicine, Inc. (Director · Since at least Jul 14, 2025); Bristol-Myers Squibb Company (EVP and President, Hematology · Nov 20, 2019 – Dec 31, 2020 · Past); Celgene Corporation (PRES., GLOBAL HEM. AND ONC. · Jun 13, 2018 – Nov 20, 2019 · Past) | President and Chief Executive Officer · Since at least Oct 18, 2021 |
| Morana Jovan-Embiricos Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Jul 29, 2020); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Feb 19, 2019 · Past) | Director · Jan 7, 2021 – Sep 16, 2021 · Past |
| Jeffrey Trigilio Other companies: XOMA Royalty Corporation (Chief Financial Officer · Since at least Jan 12, 2026) | Chief Financial Officer · Jan 7, 2021 – Feb 22, 2024 · Past |
| Mittie Doyle Other companies: Avalo Therapeutics, Inc. (Chief Medical Officer · Since at least Jul 15, 2024) | Director · Since at least Aug 7, 2025 |
| Tony Rosenberg Other companies: Radius Health, Inc. (Director · Feb 13, 2018 – Feb 26, 2020 · Past) | Director · Since at least Jan 7, 2021 |
All 17 people
| Person | Seat |
|---|---|
| Andrew Allen | Member of the Compensation Committee · Since at least Aug 7, 2025 |
| Anne-Marie Martin | Director · Since at least Mar 1, 2022 |
| Corrine Savill | Chief Business Officer · Since at least Jul 11, 2022 |
| David P Ryan | Director · Since at least Nov 1, 2022 |
| Jeffrey Alan Jones | Chief Medical Officer · Since at least Feb 28, 2022 |
| Nate Nguyen | Interim PAO and PFO · Mar 29, 2024 – Mar 29, 2024 · Past |
| Thomas Ebeling | Director · Jan 7, 2021 – Jun 10, 2024 · Past |
Log in to ask 6ix AI your own questions about Cullinan Therapeutics, Inc.